Genetically Modified Vaccines - Additional Guidance Needed? - Live Online

Wednesday, 8 December 2021 12.00 - 17.00 h

Seminar-Nr. 19459

Unfortunately, this Live Online Training cannot take place on this date. As soon as a new date is fixed, you will find the information on this page.


Petra Falb, AGES
Pierre A. Morgon, PharmD, LL.M, MRGN Advisors
Dr Bernd Renger, Bernd Renger Consulting
Dr Frank Sielaff, GMP Inspector
Dr Lyudmil Tserovski, BioNTech
Peter Walters, CRB


Genetic modification technologies were widely used for vaccine development during the COVID-19 pandemic, for other vaccines and for veterinary vaccines. Several products have been approved around the world. In the EU, products that protect against infection with an infectious organism are by definition vaccines. And as such, vaccines are excluded from the ATMP guidelines - even if technologically they use techniques known from gene therapy. Particularly in the case of approaches that were not previously approved as medicines, such as mRNA lipid nanoparticles, some companies face a regulatory environment that does not seem fully transparent to them and in which there appears to be a lack of appropriate guidance.

This Live Online Training discusses the regulatory landscape for such genetically modified vaccines, especially when these gene therapy technologies overlap with traditional vaccine areas and vaccine regulations. This workshop will highlight the current regulatory situation and use case studies from manufacturers to show the challenges and hurdles in development, manufacturing and approval. It also seeks to identify the extent to which further guidance is needed beyond the existing guideline documents. One question could also be how this is viewed internationally when the requirements or classifications of the products differ, e.g. in Europe and in the USA.


The quality of a medicinal product, and thus also that of a vaccine, is of crucial importance for its safety and efficacy and thus for its suitability for the patient. Given the growing recognition of the increasingly important role of biological medicines in healthcare worldwide, competent authorities have already published a whole range of guidelines and helpful documents. Products such as ATMPs, but also genetically modified vaccines, have the potential to transform patient and healthcare delivery worldwide.

However, the development, characterisation and manufacture of these innovative medicines is particularly challenging due to their high complexity and emerging technologies. In the course of development, transfer and manufacture, new questions often arise that also need to be clarified from the regulatory side. Are further specifications from the authorities necessary for this? Where are there still gaps? What experience have manufacturers gained so far in the approval process? Especially with a view to worldwide use.


This Live Online Training is aimed at all staff and regulatory representatives involved in the development, manufacture, quality assurance and authorisation of vaccines and/or ATMP in general and gene therapy medicines in particular.

Technical Requirements

For our Live Online Training Courses and Webinars, we use Cisco WebEx, one of the leading suppliers of online meetings.

At http://www.webex.com/test-meeting.html you can check if your system meets the necessary requirements for the participation at a WebEx meeting and at the same time install the necessary plug-in.  Please just enter your name and email address for the test. If the installation is not possible because of your rights for the computer system, please contact your IT department. WebEx is a standard nowadays and the necessary installation is fast and eas


Moderation, Welcome and Introduction
Dr Sabine Hauck, Leukocare, Chair of the ECA ATMP Interest Group and Axel H. Schroeder, Concept Heidelberg, Administration Manager of the ECA ATMP Interest Group

Current Regulatory Framework for Genetically Modified Vaccines
Petra Falb, AGES
  • Relevant Guidelines
  • Licensing regulatory background
Case Study – mRNA Product – Regulatory Requirements and Hurdles
Lyudmil Tserovski, BioNTech
  • Basic mechanism of action of mRNA based vaccines and anti-cancer ATMPs
  • GMP aspects of mRNA-based medicinal products (manufacturing and control)
  • Regulatory aspects depending on the type of medicinal product (ATMP or Vaccine)
  • Challenges concerning the supply chain and the QP certification
Regulatory GMP Landscape
Frank Sielaff, c/o Local Council Darmstadt
  • Relevant GMP Guidelines
  • What is in focus of a GMP inspection and what is not?
  • GMP challenges
Possible (Quality) Pitfalls on the Way to Marketing Authorisation
Bernd Renger, former Chair of the European QP Association
  • What quality systems and GMP compliance level to  expect
  • API and formulated API (LNP)
  • Novel excipients
    • Functional and structural lipids
    • Polymerosomes
  • Oligodeoxynucleotide adjuvants
Vaccines and Gene Therapy - Same but Different
Peter Walters, CRB
  • Way of manufacturing vs. route of administration vs. legally classification
  • The complication that vaccine technologies have evolved, but are still regulated under different conditions
  • How the future of the industry will possibly need to be updated in the wake of gene therapy innovation
Business and  Healthcare Policy Perspectives
Pierre A. Morgon, PharmD, MBA, LL.M
  • From acceptability across the entire landscape of stakeholders to the contribution to availability and accessibility

Dieses Seminar/Webinar kann nicht gebucht werden. Alternative Termine für dieses Seminar/Webinar und ähnliche Veranstaltungen finden Sie in der Übersicht nach Thema..

Für viele Seminare und Webinare gibt es auch Aufzeichnungen, die Sie jederzeit bestellen und anschauen können. Diese Aufzeichnungen finden Sie in einer themensortierten Liste.

Oder senden Sie uns Ihre Anfrage einfach über das folgende Kontaktformular.

* auch unkompliziert per Kreditkarte bezahlbar
American Express Visa Mastercard

Weitere Termine vor Ort
Weitere Termine vor Ort nicht verfügbar
Weitere Termine online
Weitere Termine online nicht verfügbar
Aufzeichnung nicht verfügbar

Haben Sie noch Fragen?

Wir stehen Ihnen für weitere Auskünfte gerne zur Verfügung.
Tel.: +49 6221 84 44 0
E-Mail: info@concept-heidelberg.de

Frau mit Headset


Teilnehmerstimmen - das sagen andere über unsere Seminare:

"Die Umsetzung mit Memberspot ist wirklich ausgezeichnet gelungen.
Es unterstützt die Wissensvermittlung und gewährleistet auch die richtige Durchführung des Kurses.”
Christian Wagener, WAGENER & CO. GmbH
GMP Basis-Einstiegsschulung (B 1) - Aufzeichnung Online Seminar, April 2024

Guter, breit gefächerter Überblick mit interessanten Verknüpfungen zur Praxis,
welche die Theorie super veranschaulicht.”
Marina Kicoranovic, Labor Hartmann GmbH
GMP/Basis-Einstiegsschulung (B 14), September 2023

Die Referenten waren sehr gut! Sie haben sehr klar gesprochen, nur sehr wenige englische Begriffe
verwendet (super) und waren sehr praxisbezogen.”
Astrid Gießler, Regierungspräsidium Karlsruhe
Live Online Seminar - Basiskurs Computervalidierung & Datenintegrität im GxP Umfeld (B 3), Juni 2023

Sehr guter Bezug zur Schulung für einen GMP-Anfänger. Habe mich sehr gut abgeholt gefühlt.”
Dr. Harald Werner, Infraserv GmbH & Co. Höchst KG
GMP-Basisschulung (B 1), Juni 2023

„Interessante Themen, gut vorgetragen, die eigenen Erfahrungen der Vortragenden helfen, dies noch besser nachzuvollziehen.“ „Gute Gestaltung der Workshops, das Zusammenarbeiten in Gruppen und der Austausch mit anderen hilft sehr.“
Manuela Seibert, Merck, GMP-Leadauditor/in (FA 2), April 2024


Bleiben Sie informiert mit dem GMP Newsletter von Concept Heidelberg!

GMP Newsletter

Concept Heidelberg bietet verschieden GMP Newsletter die Sie auf Ihren Bedarf hin zusammenstellen können.

Hier können Sie sich kostenfrei registrieren.


Kontaktieren Sie uns

Haben Sie Fragen?

Concept Heidelberg GmbH
Rischerstraße 8
69123 Heidelberg

Tel. :+49622184440
Fax : +49 6221 84 44 84
E-Mail: info@concept-heidelberg.de

zum Kontaktformular